risk of GVHD while the risk of graft failure and relapse increase. [2][3][4] Thus the short-term benefit of T cell depletion may not improve the overall survival of patients. The stanWe conducted a study to evaluate the efficacy of the combination of tacrolimus and short-course methotrexdard approach to the prevention of acute GVHD is through pharmacologic immunosuppression. Presently, most regiate for the prevention of acute GVHD in patients with hematologic malignancies. Patients received preparative mens for GVHD prophylaxis are centered on cyclosporine as the main immunosuppressant given in conjunction with regimens specific for their disease category. Twenty-six out of 28 received HLA-identical sibling transplants and various doses and schedules of methylprednisolone and/or methotrexate. [5][6][7][8][9][10] The majority of clinical trials conducted the two remaining patients received one-antigen mismatched transplants from a family member. With a over the past decade suggest the superiority of a combination of cyclosporine and a short course of methotrexate median follow-up of 14 months, the Kaplan-Meier estimate of event-free survival was 50 ؎ 9%. The probover either agent alone. In these trials, acute GVHD still developed in 8-33% of patients who received a marrow ability of grade II-IV GVHD was 15 ؎ 7%. Four patients developed GVHD: two had grade II and one graft from an HLA-matched sibling donor. Tacrolimus is a new immunosuppressive agent which is each developed grade III and IV GVHD. Administration of methotrexate was associated with severe effective in the prevention and treatment of graft rejection in solid organ transplantation. 11,12 The efficacy of tacrolmucositis and there was no correlation between the distribution of the GVHD grade and the cumulative dose imus for the prevention of acute GVHD has been shown in both murine and canine models. 13,14 Several pilot clinical of methotrexate given. Thirteen patients have died; nine from transplant-related complications and four from trials have confirmed the potential of tacrolimus as an agent for GVHD prophylaxis in allogeneic BMT. 15,16 These relapse. The major toxicity of tacrolimus was renal. Nine out of 28 patients (32%) developed renal dysfuncobservations, although preliminary, indicate that tacrolimus is an effective agent for the prevention of acute GVHD in tion attributed to tacrolimus. The combination of tacrolimus and methotrexate is an effective regimen for allogeneic BMT. In this report, we describe our results with 28 patients who received a combination of tacrolimus and GVHD prophylaxis but associated with significant renal and mucosal toxicity. Further studies of tacrolimus as short-course methotrexate for GVHD prophylaxis after allogeneic BMT from sibling donors. a single agent or in combination with either steroids or with a lower dose of methotrexate or with other antiproliferative drugs to modify the adverse events may improve the therapeutic index of this useful and promising agent.
From March to December 1995, 28 patients with hematologic malignancies received an allogeneic BMT at the UniProphylactic treatment for graft-versus-host disease versity of Michigan Medical Center. The protocols and con-(GVHD) after allogeneic bone marrow transplantation is sent forms were approved by our Institution Review Board. one of the most critical elements in the reduction of transWritten informed consent was obtained on all patients. All plant-related morbidity and mortality. 1 It is well established patients had studies of renal, pulmonary and cardiac functhat GVHD is mediated through T cells and that the tions within 2 weeks of admission. One patient was found depletion of T cells from the marrow graft eliminates the to have an ejection fraction of 40% from prior anthracycline therapy, and one other patient was found to have an elevation of creatinine to 2.7 mg% as a result of dehydration.
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Preparative regimen methotrexate was withheld. For patients with less severe renal dysfunction, the dose of methotrexate was adjusted Patients were assigned to receive a preparative regimen according to the following: 25-75% dose reduction for crebased on the underlying malignancies. One patient with atinine 2-2.5 times of baseline and 0-50% dose reduction multiple myeloma received modified total body irradiation for creatinine 1.25-2 times of baseline. For patients with (TBI) delivered by a linear accelerator in six fractions over an elevation of transaminases Ͼ200 U/l and/or total biliru-3 days to a total dose of 900 cGy. The lungs and liver were bin Ͼ5 mg%, the dose of methotrexate was reduced by at shielded during TBI; at the end of the session the shielded least 50%. Patients who had either a weight gain of Ͼ5% areas received an equivalent dose of electron beam. TBI of the admission weight, the presence of ascites or edema was then followed by a pharmacokinetically targeted dose received at least a 50% dose reduction. of busulfan to attain a steady state blood level of 650 ng/ml. Busulfan was given orally every 6 h for 16 doses and cycloStatistical analysis phosphamide 60 mg/kg was given intravenously daily for 2 days. 17 The remaining patients received a non-TBI regiThe Kaplan-Meier method was used to estimate the probmen. Ten patients with non-Hodgkin's lymphoma (36%) ability of graft-versus-host disease and event-free survival received a CVB regimen as previously described. 18 Five using BMDP software. 23 The distribution of categorical patients with CML in chronic phase received BUCY-2 regidata was compared by 2 test using StatXact software to men. 19 Nine patients received BUCY-2 with the addition calculate the exact P value for the small sample size. 24 The of Ara-C 2 g/m 2 intravenously every 12 h for four doses difference between groups of continuous variables was ('BAC' regimen). 20 Of these nine patients, five had AML, compared using Student's t-test. All P values had to be two had MDS, and one each had myelofibrosis or ALL.
р0.05 on the two-sided test to be considered significant. Three patients received 'BAC' with the addition of thio-TEPA in a phase I dose escalation study: one was a patient with resistant AML and two had CML (one in blastic phase Results and the other in accelerated phase).
Patient characteristics are shown in Table 1 . Twenty-eight patients were treated in this study. The median age was 41 Graft-versus-host disease prophylaxis (range 19-55). Twenty-six out of 28 patients (93%) received HLA-identical sibling marrow. The remaining two All patients received a combination of tacrolimus and a short course of methotrexate. Tacrolimus (Fujisawa, Deerpatients received a one-antigen disparate marrow from a family member. Sixteen donors were male and 12 were field, IL, USA) was initiated by continuous infusion on day −1 at a dose of 0.03 mg/kg/day calculated on the patients' female. Of the 12 female donors, 11 were parous. lean body weight. Once the patients tolerated oral medications, the i.v. form of tacrolimus was switched to the oral Engraftment and survival route at a conversion ratio of 1:4 and was given on a 12 h schedule. Dose modifications of tacrolimus were dependent With median follow-up for the survivors of 14 months (range 11.2-18.6 months), the Kaplan-Meier estimate of on the levels of creatinine elevation and the clinical scenario. A dose reduction of at least 25% was mandatory for the event-free survival was 50 Ϯ 9% (Ϯ s.e.) ( Figure 1 ). Seven patients died during the transplant admission. The patients with a creatinine elevated to Ͼ1.5 times baseline and at least a 50% reduction for patients with a creatinine median time from the date of BMT to discharge was 23 days (mean 28 days, range 12-80). Patients who survived Ͼ3 times baseline. Blood levels of tacrolimus were obtained twice weekly during the first 8 weeks of therapy transplantation were discharged at an average of 23 days after BMT (median 21, range 17-38). The median time to using IMx. 21 The dose of tacrolimus was adjusted to maintain blood levels between 10 and 30 ng/ml. After the first recovery of ANC у0.5 × 10 9 /l was 15 days (range 10-29 days). 8 weeks of therapy, the dose of tacrolimus was tapered 20% every 4 weeks and discontinued on day 181.
Methotrexate 15 mg/m 2 was given by i.v. bolus on day Graft-versus-host disease +1, and 10 mg/m 2 on days +3, +6 and +11 of BMT. The dose and schedule for methotrexate was similar to that The probability of grade II-IV acute GVHD was estimated at 15 Ϯ 7% by the Kaplan-Meier method (Figure 2 ). Four described by the Seattle BMT team when given in conjunction with cyclosporine.
7 Acute GVHD was graded using patients developed acute GVHD: two had grade II and one each grades III and IV. Seven patients developed chronic established criteria. 22 The decision to give methotrexate was determined by the severity of mucositis, weight gain, GVHD, three of whom had progressive chronic GVHD while four others developed de novo chronic GVHD. Two the presence of third-spacing, and the renal and liver functions on the day of the drug administration. Mucositis was of three patients with progressive chronic GVHD died from pulmonary aspergillosis, the remaining patient was alive graded using the SWOG criteria. For a grade II or III mucosal toxicity, the dose of methotrexate was modified or with extensive systemic sclerosis. One of the four patients with de novo chronic GVHD was alive with limited disease withheld according to the discretion of the physician, and for a grade IV toxicity the dose had to be reduced by at not requiring therapy; two patients had extensive disease and responded to steroids with excellent performance least 50%. In patients who developed renal dysfunction with an elevated creatinine greater than 2.5 of baseline, the status; one remaining patient died from recurrent leukemia. row on day 169. Two patients with AML relapsed at day 90 and day 255 post-BMT. One achieved a second remission prior to transplant and the other did not achieve a remission after two induction attempts. A soft tissue recurrence (chloroma) was documented in a patient who was transplanted in the blastic phase of CML. Finally, a patient with low-grade lymphoma had a nodal and marrow relapse 10 months after BMT. He is currently receiving chemotherapy and is scheduled to receive a second BMT.
Cause of death
Thirteen patients died. Nine deaths were due to transplantrelated complications: two from bleeding (one CNS and one patient with nephrolithiasis and renal insufficiency died from renal failure and two patients who had grade III and grade IV acute GVHD died from pulmonary aspergillosis Two patients were transplanted using one antigen-mismatched family donors. One patient is alive, free of disease complicating steroid-resistant acute GVHD at day 132 and day 188. Four patients died from their underlying maligand without evidence of acute or chronic GVHD; the second died early in the transplant course of a CNS bleed.
nancies; one had AML in second CR, one had refractory AML and failed two induction attempts, one had ALL in There was no correlation of the distribution of GVHD grade with the cumulative dose of methotrexate received first CR and one had blastic phase of CML.
Liver dysfunction Discussion
Hyperbilirubinemia is associated with poor outcome. None Tacrolimus represents the first of the new class of immunoof the 21 patients who survived to 100 days after BMT had suppressive agents being investigated in organ transplana bilirubin of у6 mg%, four had bilirubin between 3.1 and tation. The clinical efficacy in solid organ transplantation 6.0 mg%. Seven patients died during the first 100 days;
has spurred interest in its use in allogeneic BMT.
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two had a bilirubin of р3.0 mg%, three had a bilirubin Although tacrolimus binds to an immunophilin similar to 3.1-6.0 mg% and two had a bilirubin of у6.0 mg% (P = cyclosporine, its immunosuppressive activity is 50-to 100-0.001). The peak bilirubin had no correlation with the total fold that of cyclosporine. Using a modified limiting dilution dose of methotrexate given (P = 0.61). Two patients who analysis, Bishop et al 26 reported the differential effects of developed grade III and IV acute GVHD had bilirubin у6 cyclosporine and tacrolimus on T cell activation in vivo. mg% and two other patients with grade II GVHD had a Tacrolimus abrogated the conversion of precursor helper T bilirubin of р2 mg%. Four patients developed veno-occluslymphocytes to antigen-conditioned helper T lymphocytes, ive disease (VOD) of the liver based on clinical symptoms whereas cyclosporine at 20-fold higher concentration failed and signs. 25 VOD resolved in three patients. Two of these to exert this effect. In the murine model, Blazar et al 13 demsubsequently died from causes not related to VOD; one onstrated the reduction of mature T cell expansion in each from GI and CNS bleeding. The remaining patient response to host alloantigens by tacrolimus, resulting in a with VOD who also had nephrolithiasis died from progresslower incidence of lethal GVHD. Tacrolimus also prevents ive renal failure.
the rejection of T cell-depleted marrow allografts via similar cellular mechanisms. In the canine model, five of 10 recipients of DLA-mismatched marrow and buffy coat became long-term survivors when tacrolimus was adminisRenal insufficiency tered in conjunction with a short-course of methotrexate.
14 However, dogs may not be an appropriate model for studyTwelve out of 28 (43%) patients had an elevation of creatiing tacrolimus due to the occurrence of intussusception nine to у2 mg% during the first 180 days of BMT. In nine which is a unique drug-related adverse event in this animal. out of the 12 patients (32% of the entire population), the Nevertheless, these two animal models provide the rationrenal dysfunction was attributed to tacrolimus. The mean ale to explore further the use of tacrolimus in clinical marblood level of tacrolimus during the 2 weeks preceding the row transplantation. onset of renal dysfunction was 15.7 Ϯ 5.15 (Ϯ s.d.) ng/ml
In a pilot study reported by Nash et al, 15 18 patients (range 9-23 ng/ml) and was not significantly different from with advanced malignancies received tacrolimus alone, or those who did not develop renal dysfunction whose mean tacrolimus with either methylprednisolone or short-course tacrolimus level was 13.6 Ϯ 3.0 ng/ml (range 9.3-18.9 methotrexate. The overall cumulative incidence of grade IIng/ml, P = 0.42).
IV acute GVHD was 44%. The most significant side-effect of tacrolimus was nephrotoxicity which occurred in 14 of 18 patients (78%). There was a significant reduction of tacrolimus bioavailability in patients receiving methotrexate Other adverse events although the clearance of tacrolimus did not differ from the two groups not receiving methotrexate. The mechanisms Grade II and III mucositis occurred in 15 and 7 patients, respectively. The severity of mucositis was the primary realeading to the reduction of tacrolimus bioavailability by methotrexate is currently unknown. This finding underson for a dose reduction of methotrexate in 12 patients (42%); six with grade II and six with grade III mucositis.
scores the need to evaluate the contribution of methotrexate to the immunosuppressive activity in this combination. There was no significant difference in the distribution of the severity of mucositis among the preparative regimens
The study to address the efficacy of tacrolimus monotherapy was conducted in a multicenter phase II trial in (P = 0.19). Of the five patients who had BUCY-2, two had grade I and three had grade II mucositis. Nine patients genotypically matched BMT patients with leukemia and myelodysplasia.
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Eleven of the 27 patients (41%) received BAC; seven had grade II and two had grade III. Three patients received BACT and one each developed developed grade II-IV GVHD, however, only one patient (4%) had a grade III GVHD and none had grade IV. The grade 0, I or II mucositis. Ten patients received CVB, one had no mucositis, one had grade I, three had grade II and starting dose of tacrolimus was 0.04 mg/kg with the conversion ratio from i.v. to oral of 1:5. The main adverse effect five had grade III. One patients who received BUCY-TMI had grade I mucositis. Several patients had impending airof tacrolimus was reversible, dose-related nephrotoxicity which occurred in 92.6% of the patients. way obstruction due to confluent fibrinous mucositis; however, no patient required incubation. Saline aerosol delivOur study further supports the efficacy of tacrolimus as an immunosuppressive agent for the prevention of acute ered by face mask was routinely used in patients who developed mucositis to loosen thick secretions and for the GVHD. The low probability of acute GVHD grade II-IV of 15% may be the result of non-TBI preparative regimens ease of suctioning.
Six patients developed reversible hypertension while in 27 of the 28 patients. This observation is consistent with the report of significantly lower incidence of acute GVHD receiving tacrolimus. Two patients had paresthesia with symptomatic improvement after the tacrolimus dose was in patients with CML who received BUCY-2 as compared to those who received CY-TBI. 27 The incidence of nephroreduced.
